Data Catalog

Data from "Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases"

WSU Dataset

Authors

Anza B. Memon

Adil Javed

Christina Caon

Shitiz Srivastawa

6 more author(s)...

Description

B-cells play a pivotal role in several autoimmune diseases, including patients with immune-mediated neurological disorders (PIMND), such as neuromyelitis optica (NMO), multiple sclerosis (MS), and myasthenia gravis (MG). Targeting B-cells has been an effective approach in ameliorating both central and peripheral autoimmune diseases. However, there is a paucity of literature on the safety of continuous B-cell depletion over a long period of time. The aim of this study was to examine the long-term safety, incidence of infections, and malignancies in subjects receiving continuous therapy with a B-cell depleting agent rituximab over at least 3 years or longer. This was a retrospective study involving PIMND who received continuous cycles of rituximab infusions every 6 to 9 months for up to 7 years. The incidence of infection related adverse events (AE), serious adverse events (SAE), and malignancies were observed.

Subject

Biology

Medicine & Health

Access Rights

Free to all